Who Paid My Doc
Frank Kuo
Diagnostic Neuroimaging Stanford, CA Medical Doctor
NPI 1922418797 CMS profile 7025687
300 Pasteur Dr, Ste 200, Stanford, CA 94305
General payments
$22
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Frank Kuo of Stanford, CA is reported in the CMS Open Payments database as having received $22 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $22 | 1 |
Beside peers
- Frank Kuo
- Diagnostic Neuroimaging median
- Middle half of Diagnostic Neuroimaging
- National median
In program year 2025, general payments to Frank Kuo were reported at $0. Among 30 Diagnostic Neuroimaging profiles paid that year, the median was $109 and the middle half received between $30 and $323.
Show as a table
| Year | Frank Kuo | Diagnostic Neuroimaging median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $200 | $58–$965 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $22 | $155 | $25–$5,689 | $132 |
| 2022 | $0 | $129 | $23–$1,124 | $149 |
| 2023 | $0 | $259 | $136–$2,540 | $160 |
| 2024 | $0 | $212 | $75–$547 | $164 |
| 2025 | $0 | $109 | $30–$323 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 100 billing codesPaid by Medicare
$172,471
Medicare patients
1,264
Services billed
11,540
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 56% | |
| Ischemic heart disease | 28% | |
| Depression | 28% | |
| Diabetes | 26% | |
| Chronic kidney disease | 26% | |
| Heart failure | 19% | |
| COPD | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, gadobenate dimeglumine (multihance), per ml A9577 | Office | 207 | 2,788 | $3,688 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 79 | 6,091 | $593 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Diagnostic Neuroimaging in California
Ryan Murtagh
Diagnostic Neuroimaging · El Segundo, CA
Jeremy Heit
Diagnostic Neuroimaging · Stanford, CA
Daniel Chow
Diagnostic Neuroimaging · Orange, CA
Nancy Pham
Diagnostic Neuroimaging · Stanford, CA
Seena Dehkharghani
Diagnostic Neuroimaging · Stanford, CA
Gregory Zaharchuk
Diagnostic Neuroimaging · Stanford, CA
Related records
Diagnostic Neuroimaging in California
Practitioners in the same specialty and state, ranked by reported value.
All Diagnostic Neuroimaging
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.